NVDA
NVIDIA
-- 114.060 TSLA
Tesla
-- 284.650 TSM
Taiwan Semiconductor
-- 172.970 PLTR
Palantir
-- 83.420 AMD
Advanced Micro Devices
-- 98.230 
NEWS SUNDAY 12/8
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
Molecular Partners (NASDAQ: MOLN)presented data from two programs at ASH 2024: MP0533 phase 1/2a study and preclinical data on MP0621. The MP0533 study, targeting relapsed/refractory AML or MDS/AML, showed an acceptable safety profile in 37 patients across seven cohorts, with initial antileukemic and pharmacodynamic activity. Despite lower than anticipated drug exposure, four responders were reported. The company is amending the protocol to optimize dosing schedules.
The preclinical data for MP0621, a Switch-DARPin candidate for hematopoietic stem cell transplantation conditioning, demonstrated its intended mechanism of HSC depletion while reducing off-target effects. However, non-human primate data doesn't support its use in AML patients as previously hypothesized.
The company is now evaluating MP0621 for partnering opportunities.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Sean Parker : man, you're taking all the fun out of my day off... always posting. lol, just messing around. I love your due diligence! always give me more to look into than I planned.